CurrentmhnPolicy CP.PHAR.89

Peginterferon alfa-2a (Pegasys) — Clinical Policy

Defines medical necessity, coverage criteria, and authorization requirements for peginterferon alfa-2a (Pegasys) across Commercial, HIM, and Medicaid; affects prescribers and prior authorization reviewers.

Policy Summary

Payermhn

PolicyPeginterferon alfa-2a (Pegasys) — Clinical Policy

Policy CodePolicy CP.PHAR.89

Change TypeGuideline updates and duration standardization

Effective Date10.11

Next Review Date

Key ActionSubmit prior authorization with clinical documentation (office notes, labs) showing member meets initial or continuation criteria.

SourceLink

POLICY UPDATE CHANGES

Updated definition of significant fibrosis from stage 3-4 to stage 2-4 per 2024 WHO CHB guidelines.

Standardized approval duration for melanoma and NCCN-supported off-label uses to 6 months initial duration and 12 months continued duration.

Removed PegIntron and Sylatron brands and corresponding melanoma criteria as discontinued.

Added off-label indications per NCCN including chronic myeloid leukemia and updates to multiple myeloproliferative neoplasm indications.

For primary cutaneous CD30+ T-cell lymphoproliferative disorder clarified diagnosis as primary cutaneous anaplastic large cell lymphoma and added requirement for monotherapy use per NCCN.

6 moInitial off-label approval

12 moContinuation duration

180 mcgMax weekly dose

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial: NCCN-Recommended Off-Label Indications

Covered when ALL of the following are met for NCCN-recommended off-label indications

NCCN off-label initial: 1. Diagnosis of one of the following: a) Myeloproliferative neoplasms: i) Myelofibrosis, low risk and symptomatic; ii) Polycythemia vera; iii) Essential thrombocythemia; b) Systemic mastocytosis; c) Hairy cell leukemia, prescribed as a single agent; d) Erdheim-Chester disease; e) Primary cutaneous anaplastic large cell lymphoma, prescribed as a single agent; f) Adult T-cell leukemia or lymphoma, prescribed in combination with zidovudine; g) Mycosis fungoides or Sezary syndrome; h) Chronic myeloid leukemia during pregnancy. 2. Prescribed by or in consultation with an oncologist. 3. For Erdheim-Chester disease: used as a single agent for disease that is symptomatic or relapsed/refractory. 4. Request meets one of the following: a) Dose does not exceed 3 mcg/kg per week; b) Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

Initial: Chronic Hepatitis B Infection

Covered when ALL of the following are met for chronic hepatitis B infection

CHB initial: 1. Diagnosis of chronic hepatitis B virus infection. 2. Prescribed by or in consultation with a gastroenterologist, hepatologist, or infectious disease specialist. 3. Age ≥ 3 years. 4. ONE of the following: a) Two elevated ALT lab values within the past 12 months (≥70 IU/L for men, ≥50 IU/L for women) AND HBV DNA ≥20,000 IU/mL for HBeAg positive members or >2,000 IU/mL for HBeAg negative members; b) Diagnosis of cirrhosis, HBV DNA >2,000 IU/mL, and age ≥18 years; c) Liver biopsy showing moderate/severe necroinflammation (Grade 9-18) or significant fibrosis (Stage 2-4). 5. If age ≤17 years, member does not have cirrhosis. 6. Dose does not exceed 180 mcg per week.

Continuation Therapy

Covered when ALL of the following are met for continuation (all indications in Section I except CHC)

Continuation (non-CHC): 1. Member is currently receiving Pegasys via the benefit, or documentation supports the member has been receiving Pegasys for a covered indication for at least 30 days. 2. Member is responding positively to therapy. 3. If request is for a dose increase, request meets one of the following: a) New dose does not exceed 180 mcg per week; b) New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence). Prescribed regimen must be FDA-approved or recommended by NCCN.

Requests for use of peginterferon alfa-2a for indications that are not FDA‑approved and not specifically addressed in this policy will not be authorized unless the provider supplies sufficient documentation of efficacy and safety consistent with the referenced off‑label use policies (CP.CPA.09 for commercial, HIM.PA.154 for marketplace, CP.PMN.53 for Medicaid) or other applicable evidence of coverage documents. Treatment of chronic hepatitis C (CHC) with peginterferon alfa-2a is not authorized because interferon‑based regimens are no longer recommended per the 2018 AASLD‑IDSA HCV guidance. Other situations that are not authorized include uncontrolled autoimmune hepatitis, use following heart, lung, or kidney transplant, members with recent drug or alcohol abuse who have not abstained for ≥3 months, and use solely to reduce the risk of hepatocellular carcinoma in cirrhosis.

Osteopenia and osteoporosis are no longer listed as distinct off‑label indications in this policy; these conditions are considered potential complications of systemic mastocytosis rather than separate approved uses for peginterferon alfa-2a. As with other non‑FDA indications, requests related to osteopenia/osteoporosis require sufficient off‑label supporting evidence per the referenced off‑label policies or will be denied under the policy exclusions.

Interferon‑based regimens (including PEG‑interferon) are no longer recommended for the treatment of chronic hepatitis C per the 2018 AASLD‑IDSA HCV guidance because direct‑acting antiviral agents are now the standard of care. Consequently, the policy does not authorize peginterferon alfa-2a for CHC and lists approval duration for CHC as Not applicable. Providers should follow current AASLD‑IDSA guidance and use direct‑acting antiviral therapies for CHC management.

Initial Therapy

Initial therapy coverage rules

Initial coverage paths: Either meet the NCCN-recommended off-label indication criteria OR meet the chronic hepatitis B infection criteria. Interferon-based treatment for chronic hepatitis C is not recommended and is not an authorization pathway.

Initial durations

Initial approval durations and initial-therapy notes from annual review

Initial duration: Initial approval duration standardized to 6 months for melanoma and NCCN-supported off-label uses as of the 3Q2021 review.

Approval duration for CHB is addressed separately (48 weeks).

Continuation / Renewal Criteria

Continuation Therapy

Continuation criteria for members already receiving therapy

Continuation: 1. Member is currently receiving Pegasys via the benefit or has documentation of at least 30 days of therapy. 2. Member is responding positively to therapy. 3. Dose increase requests must meet one of the following: a) New dose does not exceed 180 mcg per week; b) New dose is supported by practice guidelines or peer-reviewed literature (prescriber must submit evidence). Prescribed regimen must be FDA-approved or NCCN-recommended.

Continuation durations: Continued duration standardized to 12 months for melanoma and NCCN-supported off-label uses as of the 3Q2021 review; up to 5 years total for melanoma; up to a total of 48 weeks for HBV.

Continuation durations

Continuation/renewal duration updates from policy annual reviews

Continuation durations:

Provider Actions & Operational Notes

Prior Authorization

Prior authorization required

Prior authorization is required for initial and continuation requests that meet the detailed criteria in this policy. Initial approval durations are 6 months for NCCN‑recommended off‑label indications (including melanoma and other listed malignancies) and specified durations for labeled indications (e.g., 48 weeks for chronic hepatitis B). Continued authorization durations are 12 months for ongoing NCCN‑supported off‑label uses (up to program limits such as up to 5 years total for melanoma or up to 48 weeks total for HBV). Interferon‑based regimens for chronic hepatitis C are not authorized (approval duration: not applicable).

Initial approval duration for NCCN‑recommended off‑label indications: 6 months
Continuation approval duration for NCCN‑supported off‑label indications: 12 months (program limits may apply; see specific criteria)
Chronic hepatitis B (CHB) approval duration: 48 weeks for initial therapy; continuation limited to total 48 weeks as applicable
Chronic hepatitis C (CHC) interferon‑based regimens: Not authorized (Approval duration: Not applicable)

Coding & Clinical Thresholds

HCPCS Codes referencedHCPCS

J3590	Unclassified biologics
S0145	Injection, pegylated interferon alfa-2a, 180 mcg per mL

inv-08: ALT thresholds

ALT thresholds (men)Two elevated ALT lab values within the past 12 months: ≥70 IU/L for men.

ALT thresholds (women)Two elevated ALT lab values within the past 12 months: ≥50 IU/L for women.

TimingBoth elevated ALT values must be within the prior 12 months.

inv-09: HBV DNA thresholds

HBeAg-positive thresholdHBV DNA ≥20,000 IU/mL for HBeAg positive members.

HBeAg-negative thresholdHBV DNA >2,000 IU/mL for HBeAg negative members.

Step Therapy & Sequencing

Requirement	Policy instruction
Interferon-based regimens for chronic hepatitis C (CHC)
Policy rationale
Reviewer action

Requirement	Policy instruction
Diagnosis of primary cutaneous CD30+ T-cell lymphoproliferative disorder (primary cutaneous anaplastic large cell lymphoma)
Therapy requirement: must be used as monotherapy per NCCN
Reviewer action: verify diagnosis and that peginterferon alfa-2a is prescribed as monotherapy

Quantity Limits

inv-29: Peginterferon alfa-2a (Pegasys) — 180 mcg

Standard dosePeginterferon alfa-2a (Pegasys) 180 mcg per week.

FormulationsAvailable as vial (180 mcg/mL) and prefilled syringe (180 mcg/0.5 mL).

RouteAdministered subcutaneously per dosing guidance.

Site of Care

Note

Subcutaneous administration — office or home

Pegasys is administered subcutaneously per dosing guidance and is available as a vial and a prefilled syringe for use in the office or at home per the site‑of‑care guidance.

Subcutaneous administration per dosing guidance (chunk 16).
Product available as vial and prefilled syringe (chunk 16).

Definitions & Abbreviations

inv-20: Peginterferon alfa-2a (Pegasys)

Molecular descriptionPegasys is a covalent conjugate of recombinant alfa-2a interferon.

Product namePeginterferon alfa-2a (Pegasys).

ClassPegylated recombinant interferon alfa-2a.

inv-21: Abbreviations

HBeAgHBeAg: hepatitis B e-antigen.

CHBCHB: chronic hepatitis B.

CHCCHC: chronic hepatitis C.

Background

Peginterferon alfa-2a (Pegasys) is a pegylated recombinant interferon alfa-2a — a covalent conjugate of recombinant alfa-2a interferon — indicated in specific viral hepatitis and certain oncologic/hematologic conditions. Clinical practice has shifted away from interferon‑based therapy for chronic hepatitis C because of the availability of safer, more effective direct‑acting antivirals; peginterferon retains limited roles in select hepatitis B and NCCN‑recommended off‑label oncology indications. Refer to the policy criteria for the specific covered diagnoses, prescriber specialty requirements, age limits, and dosing constraints.